Harbin Pharmaceutical Group Co., Ltd.

XSSC:600664 Stock Report

Market Cap: CN¥9.7b

Harbin Pharmaceutical Group Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Chuanyou Lu

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenure1.4yrs
CEO ownershipn/a
Management average tenure2yrs
Board average tenure2.2yrs

Recent management updates

Recent updates

CEO

Chuanyou Lu (62 yo)

1.4yrs
Tenure

Leadership Team

NamePositionTenureCompensationOwnership
Xiaodong Meng
VP, Secretary & Financial Director1.4yrsCN¥1.31m0.013%
CN¥ 1.3m
Haitao Jiang
Vice President3.1yrsCN¥691.90k0.0019%
CN¥ 185.2k
Jicheng Xia
Vice President2.6yrsCN¥467.60k0.0032%
CN¥ 308.3k
Bangdong Li
Vice President2.6yrsCN¥578.60k0.0016%
CN¥ 154.2k
Chuanyou Lu
President & Director1.4yrsno datano data
Guangjun Diao
Vice Presidentless than a yearno datano data
2.0yrs
Average Tenure
49.5yo
Average Age

Experienced Management: 600664's management team is considered experienced (2 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Chuanyou Lu
President & Director1.4yrsno datano data
Aidong Lou
Independent Director4.3yrsCN¥150.00kno data
Weihong Lu
Independent Director4.3yrsCN¥150.00kno data
Zhaohua Li
Independent Director4.3yrsCN¥150.00kno data
Ying Lei
Independent Director1.4yrsno datano data
Xiaoping Hu
Chairman4.3yrsno datano data
Shiwei Yin
Director3.3yrsno datano data
Zhifeng Sun
Director2.9yrsno datano data
Fangju Qiu
Employee Supervisor1.4yrsno data0.000080%
CN¥ 7.8k
Liu Mo
Director1.4yrsno datano data
Cheng Peng
Supervisor1.4yrsno datano data
Wenguang Peng
Chairman of the Supervisory Board1.4yrsno datano data
2.2yrs
Average Tenure
51yo
Average Age

Experienced Board: 600664's board of directors are not considered experienced ( 2.2 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/20 16:36
End of Day Share Price 2025/05/20 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Harbin Pharmaceutical Group Co., Ltd. is covered by 7 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Ling Bo TuChina Minzu Securities
Wayne HeChina Stock Investment Research Co. Ltd. (GZ500..com)
Liang LiangFirst Capital Securities Co. LTD.